Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Caroline J CoatsAhmad MasriRoberto Barriales VillaTheodore P AbrahamD Marshall BrinkleyBrian Lee ClaggettAlbert A HagègeSheila M HegdeCarolyn Y HoIan J KulacMatthew M Y LeeMartin S MaronIacopo OlivottoAnjali T OwensScott D SolomonJacob Tfelt HansenHugh C WatkinsDaniel L JacobyStephen B HeitnerStuart KupferFady I MalikLisa MengAmy WohltmanJames L Januzzinull nullPublished in: European heart journal (2024)
NT-proBNP and hs-cTnI concentrations are associated with key variables in oHCM. Serial measurement of NT-proBNP and hs-cTnI appears to reflect clinical response to aficamten therapy.